Increased incidence of herpes zoster among patients with systemic lupus erythematosus

被引:77
作者
Chakravarty, E. F. [1 ]
Michaud, K. [2 ,3 ]
Katz, R. [4 ]
Wolfe, F. [2 ]
机构
[1] Oklahoma Med Res Fdn, Div Arthrit & Clin Immunol, Oklahoma City, OK 73104 USA
[2] Univ Nebraska Med Ctr, Dept Rheumatol, Omaha, NE USA
[3] Univ Kansas, Sch Med, Lawrence, KS 66045 USA
[4] Rush Univ, Med Ctr, Dept Med, Chicago, IL USA
关键词
Shingles; herpes zoster; systemic lupus erythematosus; vaccination; incidence; risk factor; NATIONAL-DATA-BANK; RISK-FACTORS; ASSOCIATION; RESPONSES; DISEASES; VACCINE; VIRUS; OLDER;
D O I
10.1177/0961203312470186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune diseases, including systemic lupus erythematosus (SLE). We examined the incidence and risk factors for HZ in a prospective cohort of patients with physician-diagnosed SLE compared to those diagnosed with noninflammatory musculoskeletal conditions (MSK). After excluding participants with a history of prior HZ at enrollment, we followed 1485 SLE patients and 2775 MSK with semi-annual mailed questionnaires for incident HZ between 2001 and 2010. Age-adjusted incidences were calculated for each group and Cox proportional hazard models were used to identify predictors of HZ. Zostavax(R) vaccination rates were compared between groups. Participants had a mean age of 60 years at enrollment, with 13.9 years of disease. SLE patients had more HZ at all ages, with an age-adjusted incidence of 12.0/1000 person-years compared to MSK (8.7/1000 person-years) and a hazard ratio of 1.7 (95% CI 1.08-2.71) for SLE. Increasing age and reduced functional status were independent predictors of HZ. In SLE, prednisone and mycophenolate mofetil use conferred additional risk. SLE had the lowest HZ vaccination rates among age-eligible subjects. Lupus (2013) 22, 238-244.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 23 条
  • [1] [Anonymous], ZOST PACK INS
  • [2] Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus
    Borba, Eduardo F.
    Ribeiro, Ana C. M.
    Martin, Patricia
    Costa, Luciana P.
    Guedes, Lissiane K. N.
    Bonfa, Eloisa
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : 119 - 122
  • [3] Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14
  • [4] Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort
    Chen, Hsin-Hua
    Chen, Yi-Ming
    Chen, Tzeng-Ji
    Lan, Joung-Liang
    Lin, Ching-Heng
    Chen, Der-Yuan
    [J]. CLINICS, 2011, 66 (07) : 1177 - 1182
  • [5] Mycophenolate mofetil in the treatment of systemic lupus erythematosus
    Dall'Era, Maria
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (05) : 454 - 458
  • [6] Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
  • [7] Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study
    Hata, A.
    Kuniyoshi, M.
    Ohkusa, Y.
    [J]. INFECTION, 2011, 39 (06) : 537 - 544
  • [8] Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients
    Houssiau, Frederic A.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2012, 14 (01)
  • [9] KAHL LE, 1994, J RHEUMATOL, V21, P84
  • [10] Normative values for the health assessment questionnaire disability index -: Benchmarking disability in the general population
    Krishnan, E
    Sokka, T
    Häkkinen, A
    Hubert, H
    Hannonen, P
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (03): : 953 - 960